Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Other ICR Research
  • View item
  • Home
  • ICR Divisions
  • Other ICR Research
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.

Thumbnail
View/Open
Accepted version (754.7Kb)
Date
2017-06
ICR Author
Tutt, Andrew
Author
Denkert, C
Liedtke, C
Tutt, A
von Minckwitz, G
Type
Journal Article
Metadata
Show full item record
Abstract
Triple-negative breast cancer is a heterogeneous disease and specific therapies have not been available for a long time. Therefore, conventional chemotherapy is still considered the clinical state of the art. Different subgroups of triple-negative breast cancer have been identified on the basis of protein expression, mRNA signatures, and genomic alterations. Important elements of triple-negative breast cancer biology include high proliferative activity, an increased immunological infiltrate, a basal-like and a mesenchymal phenotype, and deficiency in homologous recombination, which is in part associated with loss of BRCA1 or BRCA2 function. A minority of triple-negative tumours express luminal markers, such as androgen receptors, and have a lower proliferative activity. These biological subgroups are overlapping and currently cannot be combined into a unified model of triple-negative breast cancer biology. Nevertheless, the molecular analysis of this disease has identified potential options for targeted therapeutic intervention. This has led to promising clinical strategies, including modified chemotherapy approaches targeting the DNA damage response, angiogenesis inhibitors, immune checkpoint inhibitors, or even anti-androgens, all of which are being evaluated in phase 1-3 clinical studies. This Series paper focuses on the most relevant clinical questions, summarises the results of recent clinical trials, and gives an overview of ongoing studies and trial concepts that will lead to a more refined therapy for this tumour type.
URI
https://repository.icr.ac.uk/handle/internal/845
DOI
https://doi.org/10.1016/s0140-6736(16)32454-0
Collections
  • Other ICR Research
Subject
Lymphocytes, Tumor-Infiltrating
Humans
Ubiquitin-Protein Ligases
BRCA2 Protein
Antineoplastic Agents
Neoadjuvant Therapy
Gene Expression Profiling
Genomics
Mutation
Female
Molecular Targeted Therapy
Triple Negative Breast Neoplasms
Biomarkers, Tumor
Language
eng
Date accepted
2016-11-09
License start date
2017-06
Citation
Lancet (London, England), 2017, 389 (10087), pp. 2430 - 2442

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.